Compare AVIR & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVIR | PROF |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 199.3M |
| IPO Year | 2020 | N/A |
| Metric | AVIR | PROF |
|---|---|---|
| Price | $3.18 | $7.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 415.4K | 105.5K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $2.46 | $3.76 |
| 52 Week High | $4.02 | $7.99 |
| Indicator | AVIR | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 67.28 |
| Support Level | $2.99 | $6.09 |
| Resistance Level | $3.24 | $7.04 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 79.03 | 92.42 |
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.